Literature DB >> 16059664

Free energy perturbation approach to the critical assessment of selective cyclooxygenase-2 inhibitors.

Hwangseo Park1, Sangyoub Lee.   

Abstract

The discovery of selective cyclooxygenase-2 (COX-2) inhibitors represents a major achievement of the efforts over the past few decades to develop therapeutic treatments for inflammation. To gain insights into designing new COX-2-selective inhibitors, we address the energetic and structural basis for the selective inhibition of COX isozymes by means of a combined computational protocol involving docking experiment, force field design for the heme prothetic group, and free energy perturbation (FEP) simulation. We consider both COX-2- and COX-1-selective inhibitors taking the V523I mutant of COX-2 to be a relevant structural model for COX-1 as confirmed by a variety of experimental and theoretical evidences. For all COX-2-selective inhibitors under consideration, we find that free energies of binding become less favorable as the receptor changes from COX-2 to COX-1, due to the weakening and/or loss of hydrogen bond and hydrophobic interactions that stabilize the inhibitors in the COX-2 active site. On the other hand, COX-1-selective oxicam inhibitors gain extra stabilization energy with the change of residue 523 from valine to isoleucine because of the formations of new hydrogen bonds in the enzyme-inhibitor complexes. The utility of the combined computational approach, as a valuable tool for in silico screening of COX-2-selective inhibitors, is further exemplified by identifying the physicochemical origins of the enantiospecific selective inhibition of COX-2 by alpha-substituted indomethacin ethanolamide inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16059664     DOI: 10.1007/s10822-005-0098-5

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  52 in total

Review 1.  Cyclooxygenases: structural, cellular, and molecular biology.

Authors:  W L Smith; D L DeWitt; R M Garavito
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

Review 2.  Cox-2-selective inhibitors: the new super aspirins.

Authors:  D L DeWitt
Journal:  Mol Pharmacol       Date:  1999-04       Impact factor: 4.436

Review 3.  Cyclooxygenase (COX) inhibitors: a comparative QSAR study.

Authors:  Rajni Garg; Alka Kurup; Suresh Babu Mekapati; Corwin Hansch
Journal:  Chem Rev       Date:  2003-03       Impact factor: 60.622

4.  QSAR and classification models of a novel series of COX-2 selective inhibitors: 1,5-diarylimidazoles based on support vector machines.

Authors:  H X Liu; R S Zhang; X J Yao; M C Liu; Z D Hu; B T Fan
Journal:  J Comput Aided Mol Des       Date:  2004-06       Impact factor: 3.686

5.  Thalidomide and its analogues as cyclooxygenase inhibitors.

Authors:  Tomomi Noguchi; Rumiko Shimazawa; Kazuo Nagasawa; Yuichi Hashimoto
Journal:  Bioorg Med Chem Lett       Date:  2002-04-08       Impact factor: 2.823

6.  Amide derivatives of meclofenamic acid as selective cyclooxygenase-2 inhibitors.

Authors:  Amit S Kalgutkar; Scott W Rowlinson; Brenda C Crews; Lawrence J Marnett
Journal:  Bioorg Med Chem Lett       Date:  2002-02-25       Impact factor: 2.823

7.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.

Authors:  R G Kurumbail; A M Stevens; J K Gierse; J J McDonald; R A Stegeman; J Y Pak; D Gildehaus; J M Miyashiro; T D Penning; K Seibert; P C Isakson; W C Stallings
Journal:  Nature       Date:  1996 Dec 19-26       Impact factor: 49.962

Review 8.  Cyclooxygenase inhibitors--current status and future prospects.

Authors:  G Dannhardt; W Kiefer
Journal:  Eur J Med Chem       Date:  2001-02       Impact factor: 6.514

9.  Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.

Authors:  Xueqin Song; Ho-Pi Lin; Amy J Johnson; Ping-Hui Tseng; Ya-Ting Yang; Samuel K Kulp; Ching-Shih Chen
Journal:  J Natl Cancer Inst       Date:  2002-04-17       Impact factor: 13.506

10.  Role of Val509 in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents.

Authors:  Q Guo; L H Wang; K H Ruan; R J Kulmacz
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

View more
  3 in total

1.  Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding Network.

Authors:  Shu Xu; Daniel J Hermanson; Surajit Banerjee; Kebreab Ghebreselasie; Gina M Clayton; R Michael Garavito; Lawrence J Marnett
Journal:  J Biol Chem       Date:  2014-01-14       Impact factor: 5.157

Review 2.  Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond.

Authors:  Shu Xu; Carol A Rouzer; Lawrence J Marnett
Journal:  IUBMB Life       Date:  2014-12-23       Impact factor: 3.885

3.  Accurate calculation of mutational effects on the thermodynamics of inhibitor binding to p38α MAP kinase: a combined computational and experimental study.

Authors:  Shun Zhu; Sue M Travis; Adrian H Elcock
Journal:  J Chem Theory Comput       Date:  2013-07-09       Impact factor: 6.006

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.